

GLOBAL PRENATAL & MATERNAL DIAGNOSTIC MARKET ANALYSIS TO 2020



Global Prenatal, Maternal & Carrier Diagnostic Market Analysis to 2021

Published Sept 2016

1.0 Introduction

Prenatal tests (fetus, embryos and newborns) currently on the market analyze chromosomes, DNA, RNA, genes, and/or gene products to determine whether an abnormality is present that is causative of a specific disease. Since 2011, the launch of noninvasive prenatal tests (NIPTs) is revolutionizing the prenatal screening industry providing detection rates of >99% and false positive rates of <0.1%. These screening results are only indicative of the risk and not confirmative. To confirm positive results of NIPT screening tests, prenatal diagnostic tests such as amniocentesis and chorionic villus sampling (CVS) are performed. Prior to NIPTs, ultrasound and maternal serum tests were routinely used to screen fetus for genetic abnormalities.

Globally, 50 countries have effective newborn genetic test programs, the implementation of which is in various stages. In the U.S., four million newborns are tested annually, with 3,000 found to have metabolic and genetic diseases. The purpose of newborn screening is to identify affected newborns quickly and provide them with treatment to prevent mental retardation, prolonged illness and death. The newborn genetic screening market is crowded with different technologies, the common being tandem mass spectrometry, pulse oximetry, enzyme-based assays, DNA assays and electrophoresis.

Preimplantation genetic screening and preimplantation genetic diagnosis (PGS/PGD) are genetic tests performed in eight-celled embryos before implantation during in vitro fertilization (IVF) for the detection of genetic abnormalities and sex. These tests can detect and diagnose chromosomal rearrangements, X-linked diseases and help in reducing the incidence of spontaneous abortions, increase implantation rates, prevent trisomic offsprings and avoid the risk of transmitting single gene disorders. However, PGS and PGD results are not 100% accurate and after pregnancy, if required the diagnostic tests such as amniocentesis and CVS are to be performed to confirm the positive results of PGS/PGD. In the U.S. alone, more than 63,000 babies were born through IVF in 2013 and compared to 2012 data; it was an increase of 2,000 births.

The most important development in the field of prenatal screening, is the introduction of NIPTs using cell-free fetal DNA (cffDNA) in 2011. Obstetricians and patients who are deterred by the 10% to 15% false positive rates of ultrasound screening and 5% false positive rates of maternal serum tests are eagerly embracing NIPTs which claim to have only <0.1% of false positive results.

Within just four years, molecular genetics firms have successfully produced eight different types of kits for the detection of genetic abnormalities in the fetus. These products have been gradually marginalizing the maternal serum tests and in another decade, maternal serum tests are expected to become obsolete. If, companies can develop NIPTs with a 100% accuracy rate, maternal serum tests, amniocentesis and CVS will all be completely overshadowed by NIPTs. Despite the growing popularity of NIPTs, maternal serum tests still continue to have some market due to their low price. While the maternal serum tests are available for just \$150 to \$200, NIPTs are priced between \$795 and \$2,762. However, Sequenom reportedly sold over 150,000 tests in 2013 and so pricing does not seem to be a deterrent factor. The introduction of technologies such as digital PCR and next-generation sequencing (NGS) or massively parallel sequencing (MPS) have also enabled accurate estimation of very small differences in chromosome-specific sequences in maternal blood.

1.1 Executive Summary

According to WHO, nearly 140 million babies are born every year, out of which 5 million die in the first month of life, mostly in developing countries. For example, in India, about 5% to 15% of sick newborns have a metabolic disorder. This emphasizes the need for newborn screening for preventing disability and death by early intervention, follow-up and counselling.

Globally, the use of maternal serum marker screening and ultrasound imaging for the detection of chromosome aneuploidies and other birth defects constitute a routine part of prenatal care in the first and/or second trimesters. Yet, both of these techniques have the disadvantages of high false positive rates, varying from 2% to 7%. If the results of these tests show that a fetus is at increased risk of aneuploidy, invasive approaches such as chorionic villus sampling (CVS) or amniocentesis are recommended for diagnosis.

Fetal Ultrasound Screening Market

Today, ultrasound is used on average five times per pregnancy before delivery. The fetal ultrasound screening market generated revenues of about \$x million in 2015 with the potential to earn \$x million in 2021, growing at a CAGR of x%. Fetal MRI prenatal screening is performed rarely, only when the ultrasound screening provides an ambiguous result and to detect suspected central nervous system (CNS) disorders in the fetus during the second trimester. The fetal MRI segment had generated estimated revenue of \$x million in 2015 with a potential to earn \$x million in 2021.

Maternal Serum Testing Market

The global maternal serum test market was worth \$x million in 2015 and is forecast to grow and reach \$x million by 2021. The market consists of test methods for:

- Pregnancy-associated plasma protein (PAPP-A)
- Alpha-fetoprotein (AFP)
- Human chorionic gonadotropin (hCG)
- Estriol
- Inhibin-A

Had it not been for the launch of noninvasive prenatal tests (NIPTs) in 2011, this market would have fared much better.

Noninvasive Prenatal Test Market

Noninvasive prenatal tests (NIPTs) are the future of prenatal screening and have shown signs of surpassing the traditional maternal serum test revenues by earning about \$x million in 2015. With a CAGR of x%, this market is forecast to reach \$x million in 2021.

Newborn Screening Market

Newborn screening is an accepted national health policy in about 52 countries. It is a well-entrenched routine of newborn care in the U.S., U.K., Japan, Australia and most western European countries for the last three decades. In the Asian continent, China, Philippines and Thailand have developed admirable newborn screening programs in a relatively short period of time. Mass spectrometry has become the standard technique for newborn screening. Using this technique, medical technologists are capable of screening as many as 30 metabolic disorders from a single sample of blood. The global market for newborn screening has been valued at \$x million in 2015 and it will be worth about \$x million by 2021.

Preimplantation Genetic Diagnosis Market


Preimplantation genetic diagnosis (PGD) has been in practice for more than twenty years in about 60 countries globally. PGD testing is performed to identify genetic defects in embryos. The tests are usually performed in cases of a known genetic defect, in late age pregnancy, or in patients with a history of repeated miscarriages. PCR, FISH, CGH, and SNP analysis are some of the most common techniques used, and PCR is the most widely used technology. The global market for PGD was worth about \$x million in 2015 and this has been predicted to enlarge and reach \$x million in 2021.

Table 1.1: Summary of Prenatal Screening, Prenatal Diagnosis, Newborn Screening and PGS/PGD Markets, Through 2021

Type of Test	2014 (\$ Millions)	2015 (\$ Millions)	2021 (\$ Millions)	% CAGR 2015-2021
Prenatal screening:				
Ultrasound screening				
Fetal MRI screening				
Maternal serum screening				
Noninvasive prenatal screening (NIPT)				
Total for prenatal screening				
Prenatal diagnosis (amniocentesis and CVS)				
Newborn screening				
PGS/PGD				
Total				

Source: www.kellyscipub.com

Figure 1.1: Summary of Prenatal Screening, Prenatal Diagnosis, Newborn Screening and PGS/PGD Markets, Through 2021



Source: www.kellyscipub.com

1.2 Objectives of this Report

Since the 1960s, technologies for testing fetuses for conditions including trisomies have been continually advancing. The initial nongenetic testing such as ultrasound and serum screening for protein level markers, have developed remarkably throughout the years. Yet, these conventional tests are limited in sensitivity and specificity. Parallel to the development of these conventional technologies, two invasive techniques called amniocentesis and chorionic villus sampling (CVS) were introduced in 1980s to offer near 100% detection rates for trisomies. Yet, the chances of injury to the fetus and the consequence of miscarriages deterred both patients and obstetricians from using these techniques and to this date the techniques are used in high-risk pregnancies for the confirmation of positive results from screening tests.

When human genome sequencing was successfully accomplished, experts in the healthcare industry expected that DNA sequencing would mainly focus on genetic diseases in adults. Instead, the impact of sequencing technology has been primarily on prenatal, newborn and PGD tests. In a short span of four years, the different types of maternal serum screening tests and fetal ultrasound tests are getting gradually replaced by the new technology of non-invasive prenatal tests (NIPTs). In the past four years, hundreds and thousands of these new tests have been performed in screening cfDNA from maternal blood.

The objective of this report is to provide an overview of the various technologies being employed for detecting genetic diseases in embryos, fetuses and newborns. The various chapters describe common pregnancy disorders, numerical chromosome disorders and structural chromosome disorders, single gene disorders inherited by fetuses, newborns and embryos. The global prenatal and maternal diagnostic test market is assessed with respect to:

- Fetal Ultrasound
- Prenatal MRI Screening
- Maternal Serum Screening Tests
- Noninvasive Prenatal Tests (NIPTs) using cfDNA
- NIPTs by Product
- Prenatal Diagnostic Invasive Tests
- Newborn Screening for Genetic Diseases
- Newborn Screening Market by Technology
- Preimplantation Screening/Diagnosis (PGS/PGD)

SWOT and merger/acquisition analysis is also performed as is a comprehensive documentation of the legislation pertaining to newborn screening by geography and how clinical programs are implemented in developed and developing markets.

Emerging trends in associated markets are also analysed in order to give the reader a comprehensive overview of how prenatal and maternal diagnostic testing is affected by the following industries:

- Molecular Diagnostics Market
- Liquid Biopsy Market
- Personalized Medicine Diagnostics Market
- In vitro Diagnostics (IVD) Market

1.3 Key Questions Answered in this Report

- What are the major prenatal pregnancy complications?
- What are the major genetic diseases detected in fetuses?
- What are the appropriate technologies for the detection of aneuploidies, microdeletions, duplications, copy number variations and translocations?
- How far is genetic counseling important in educating pregnant women and healthcare professionals?
- What is the impact of recent advances in clinical genomics on genetic counseling?
- What different noninvasive and invasive prenatal screening tests are performed during a pregnancy?
- What are the detection rate, true positive rate and true negative rate for NIPTs?
- Currently, in which countries are the NIPTs available?
- What is the cost of NIPTs region-wise?
- What is the uptake of conventional maternal serum tests, NIPTs and invasive diagnostic tests in the U.S.?
- What is the average cost of maternal serum screening, NIPTs, fetal ultrasound screening and invasive diagnostic tests in the U.S.?
- What are the strategies to be adopted for clinical implementation of NIPTs for all pregnancies?
- What is the “patient directed model” for the integration of NIPTs into healthcare systems?
- How does the detection rate of NIPTs compare with the rates of conventional maternal serum screening tests?
- What are the genetic disorders detectable by different prenatal screening and diagnostic tests?
- What is the reliability of amniocentesis and CVS results?
- Is the future of invasive diagnostic tests uncertain?
- Do the intact fetal cells in maternal blood have use in noninvasive prenatal diagnosis (NIPD)?
- What about the use of trophoblast cells obtained from cervix in NIPD?
- How many genetic conditions are detected during newborn genetic screening in the U.S.?
- What is the status of newborn genetic screening in developed, developing and other countries?
- What are the different preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD)?
- What are the currently available PGS/PGD testing products available in the market?
- What are the currently used advanced technologies in prenatal, newborn and PGD testing?
- What is the global market for fetal ultrasound screening, through 2021?
- Who are the market leaders in fetal ultrasound systems?
- What is the global and regional market for prenatal screening by fetal MRI, through 2021?
- What is the global and regional market for maternal screening tests, through 2021?
- What is the global and regional market for NIPTs using cfDNA, through 2021?
- What is the global and regional market for invasive prenatal diagnostic tests, through 2021?
- What is the global and regional market for newborn screening tests, through 2021?
- What is the global market for newborn screening tests by technology, through 2021?
- What is the global and regional market for pre-implantation genetic diagnosis (PGD), through 2021?
- What is the global market for molecular diagnostics, through 2021?
- What is the global market for liquid biopsy tests, through 2021?

- What is the overall global market for personalized medicine diagnostics, through 2021?
- What is the overall global market for *in vitro* diagnostics (IVD), through 2021?
- What are the recent acquisition activities in prenatal screening industry?
- What are the important factors that drive the growth of prenatal and newborn genetic testing industry?
- What are the challenges faced by the prenatal screening industry?
- What are the possible future developments in prenatal screening industry?

TABLE OF CONTENTS

1.0	Introduction	24
1.1	Executive Summary	25
1.2	Objectives of this Report	28
1.3	Key Questions Answered in this Report	28
2.0	Prenatal Pregnancy Complications: An Overview	31
2.1	Advanced Maternal Age (AMA)	31
2.1.1	Risk of Down Syndrome with Increased AMA	31
2.1.2	Risk of Miscarriage with Increased AMA	32
2.1.3	Risk of Cesarean Section with Increasing AMA	33
2.1.4	Risk of Gestational Diabetes with AMA	34
2.1.5	Risk for Pregnancy-Induced Hypertension with AMA	35
2.1.6	Risk of Placenta Previa with AMA	35
2.1.7	Delayed First Pregnancy in the U.S.	36
2.1.7.1	First Birth Rates for 35-39 Aged U.S. Women by Race	37
2.2	Pre-Existing Maternal Medical Conditions	39
2.2.1	Pregnancy Outcome in Women with Renal Disease	40
2.2.2	Pregnancy Outcome in Diabetic Women	41
2.2.3	Pregnancy Outcome in Women with Pre-Existing Thyroid Disease	41
2.2.4	Pregnancy Outcome in Obese Women	41
2.2.5	Pregnancy Outcome in Asthmatic Women	42
2.2.6	Pregnancy Outcome in Women with Epilepsy	43
2.2.7	Pregnancy Outcome in Women with Autoimmune Diseases	43
2.2.8	Pregnancy Outcome in Women with Hemoglobinopathies	44
2.2.9	Pre-Existing Chronic Diseases among Women of Reproductive Ages in the U.S.	45
2.2.9.1	Chronic Disease Risk Behaviors and Risk Factors among Women of Reproductive Ages in the U.S.	46
2.3	Medical Conditions Occurring During Pregnancy	47
2.3.1	Preeclampsia (Toxemia)	47
2.3.1.1	Prevalence of Preeclampsia in the U.S.	47
2.3.2	Gestational Diabetes in the U.S.	49
2.3.2.1	Prevalence of Gestational Diabetes in the U.S.	49
2.4	Pregnancy-Related Issues	51
2.4.1	Premature Labor	51
2.4.1.1	Common Medical Complications in Premature Babies	52
2.4.1.2	Global Prevalence of Preterm Labor	52
2.4.1.3	Prevalence of Preterm Births in the U.S. by Stage	53
2.4.1.4	Prevalence of Preterm Births in the U.S. by Race/Ethnicity	53
2.4.1.5	Prevalence of Preterm Births in the U.S. by Plurality of Birth	54
2.4.1.6	Prevalence of Preterm Births in the U.S. by Maternal Age	55

2.4.1.7	Multiple Births in the U.S.	56
2.4.2	Placenta Previa	57
2.4.3	Breech Presentation	57
2.4.4	Meconium Stained Liquor	58
2.4.5	Oligohydramnios and Polyhydramnios	58
2.5	Fetal Problems	59
2.5.1	Fetal Growth Restriction	59
2.5.2	Imperforate Anus	60
2.5.3	Congenital Heart Disease	60
3.0	Types of Genetic Diseases in Fetuses: An Overview	62
3.1	Single Gene Disorders	62
3.1.1	Autosomal Dominant Genetic Disorders	62
3.1.1.1	Huntington Disease (HD)	63
3.1.1.2	Familial Hypercholesterolaemia (FH)	64
3.1.1.3	Marfan syndrome	64
3.1.1.4	Myotonic Dystrophy	65
3.1.2	Autosomal Recessive Genetic Disorders	67
3.1.2.1	Cystic Fibrosis (CF)	67
3.1.2.2	Canavan Disease	71
3.1.2.3	Neutropenia	72
3.1.2.4	Ellis-van Creveld Syndrome (EVC)	72
3.1.2.5	Familial Mediterranean fever (FMF)	73
3.1.2.6	Faconi Anemia (FA)	73
3.1.2.7	Gaucher Disease	74
3.1.2.8	Mucopolysaccharidosis (MPSs)	74
3.1.2.9	Phenylketonuria (PKU)	75
3.1.2.10	Sickle Cell Disease	75
3.1.2.11	Beta-Thalassaemia	76
3.1.2.12	Inheritance Pattern of Autosomal Recessive Genetic Disorders	77
3.1.2.13	Chances of Inheriting a Single Gene Disorder	80
3.1.2.14	Common Recessive Disease Traits in Selected Ethnic Groups	80
3.1.2.15	Comprehensive List of Common Single Gene Disorders	81
3.1.3	X-Linked Dominant Genetic Disorders	82
3.1.3.1	Hypophosphotemic Rickets	83
3.1.3.2	Incontinentia Pigmenti	83
3.1.3.3	Focal Dermal Hypoplasia	83
3.1.3.4	Orofaciodigital Syndrome	84
3.1.3.5	Inheritance of Sex-Linked Dominant Disorders	84
3.1.4	X-Linked Recessive Disorders	85
3.1.4.1	Lesch-Nyhan Syndrome	86
3.1.4.2	Menkes Disease (Kinky hair syndrome)	86
3.1.4.3	Hemophilia A and B	87
3.1.4.4	Fabry's Disease	88
3.1.4.5	Wiskott-Aldrich syndrome (WAS)	88
3.1.4.6	Bruton's Aggamaglobulinemia	89
3.1.4.7	Color Blindness	89
3.1.4.8	Complete Androgen Insensitivity Syndrome	90
3.1.4.9	Inheritance of X-Linked Recessive Traits	90
3.2	Chromosomal Disorders	92
3.2.1	47, XXY (Klinefelter Syndrome)	93
3.2.1.1	Prenatal Diagnosis of Klinefelter Syndrome	93

3.2.2	47, XYY Syndrome	94
3.2.2.1	Diagnosis of 47, XYY Syndrome	94
3.2.3	45, X Syndrome (Turner Syndrome)	94
3.2.3.1	Prenatal Diagnosis of Turner Syndrome	95
3.2.4	47, XXX (Triple X Syndrome)	96
3.2.4.1	Tests for Triple X Syndrome	96
3.2.5	Trisomy 21 (Down Syndrome)	96
3.2.5.1	Tests for Down Syndrome	97
3.2.5.2	Incidence of Down Syndrome by Maternal Age	98
3.2.5.3	Developmental Delay in Children with Down Syndrome	99
3.2.6	Trisomy 18 (Edward's Syndrome)	99
3.2.6.1	Prenatal Diagnosis of Trisomy 18	99
3.2.6.2	Clinical Manifestations of Trisomy 18	100
3.2.7	Trisomy 13 (Patau Syndrome)	100
3.2.7.1	Prenatal Diagnosis of Trisomy 13	101
3.2.8	Triploid Syndrome	102
3.2.8.1	Congenital Anomalies Associated with Triploidy	102
3.2.8.2	Prenatal Diagnosis of Triploidy	103
3.2.9	Prevalence of Trisomies in the U.S.	103
3.2.9.1	Trisomies and Abortions	104
3.2.10	Maternal Age-Related Frequencies of Aneuploid Fetuses	104
3.2.11	Clinical Features of Common Chromosomal Aneuploidy	105
3.2.12	Maternal Age and Chromosomal Aneuploidy	105
3.2.13	Sensitivity and Specificity of Maternal Serum and Ultrasound Tests for Aneuploids	106
3.3	Structural Chromosomal Abnormalities	107
3.3.1	Autosomal Deletions	107
3.3.1.1	Wolf-Hirschhorn Syndrome (WHS)	107
3.3.1.2	Cri du chat Syndrome	108
3.3.1.3	Langer-Giedion Syndrome	108
3.3.2	Common Autosomal Microdeletion Syndrome	109
3.3.2.1	Williams Syndrome	110
3.3.2.2	WAGR Syndrome	111
3.3.2.3	Prader-Willi Syndrome (PWS)	112
3.3.2.4	Angelman Syndrome	113
3.3.2.5	Miller-Dieker Syndrome	114
3.3.2.6	Smith-Magenis Syndrome (SMS)	114
3.3.2.7	Alagille Syndrome (ALGS)	115
3.3.2.8	CATCH 22 Syndrome	116
3.3.2.9	DiGeorge Syndrome	117
3.3.3	Autosomal Duplication Syndromes	117
3.3.3.1	Beckwith-Wiedemann Syndrome (BWS)	118
3.3.3.2	Charcot-Marie-Tooth Disease Type 1A (CMT1A)	119
3.3.3.3	Cat-Eye Syndrome	120
3.3.4	Appropriate Technologies for the Detection of Microdeletions, Duplications and Copy Number Variants	121
4.0	Genetic Counseling: An Overview	122
4.1	Impact of Recent Advances in Clinical Genomics on Genetic Counseling	123
4.2	Genetic Counselors in DTC GT Industry	123
4.2.1	Types of Genetic Counseling Offered by DTC GT Companies	124
4.2.2	Roles of Genetic Counselors in DTC GT Industry	126
5.0	Prenatal Screening for Genetic Diseases: An Overview	126

5.1	Routine Prenatal Screening Tests	126
5.2	Less-Routine Prenatal Screening Tests	126
5.3	Beta Human Chorionic Gonadotropin (β -hCG) Screening Test	127
5.3.1	hCG Kits and Manufacturers	128
5.4	First Trimester Pregnancy-Associated Plasma Protein-A (PAPP-A) Screening Test	128
5.5	Maternal Serum Alpha-Fetoprotein (MSAFP) Screening Test	129
5.6	Second Trimester Serum β -hCG Screening Test	129
5.7	Second Trimester Unconjugated Estriol (uE3) Screening Test	129
5.8	Second Trimester Inhibin-A Screening Test	130
5.9	Second Trimester Hexosaminidase Test	130
5.10	Second Trimester Triple-Screen Quad Screen Tests	130
5.11	Second Trimester Screening of Cell-Free Fetal DNA (cffDNA)	131
5.11.1	Sensitivity and Specificity of NIPTs	131
5.11.2	Diagnostic Applications of cffDNA	132
5.11.3	Time of Availability of cffDNA in Maternal Blood	132
5.11.4	The Cost of NIPTs	133
5.11.5	Cost of NIPTs by Product	133
5.11.6	History of Aneuploidy Testing from 1970s to 2011	134
5.11.7	NIPT Methods of Detecting Aneuploidy	134
5.11.7.1	Shotgun Method	134
5.11.7.2	Targeted Massively Parallel Sequencing (t-MPS)	135
5.11.7.3	Single Nucleotide Polymorphisms (SNPs)	135
5.11.8	Comparison of Amniocentesis and NIPT	135
5.11.9	Advantages of NIPTs	136
5.11.10	Disadvantages of NIPTs	137
5.11.11	Comparison of Performance Criteria for Commonly used Prenatal Tests	137
5.11.12	Comparison of NIPT Detection Rates with Traditional Tests	138
5.11.13	False Positive Rates of NIPTs Compared with Those of Traditional Tests	138
5.11.14	Fetal Genetic Disorders Detected by NIPTs and other Screening Tests	139
5.12	First Trimester Ultrasound Screening Test	139
5.12.1	Nuchal Translucency (NT) Screening Test	140
5.13	Magnetic Resonance Imaging (MRI) in Prenatal Screening	141
5.14	Prenatal Diagnosis of Genetic Disorders	141
5.14.1	Amniocentesis (AC)	142
5.14.1.1	Reliability of Amniocentesis	142
5.14.2	Chorionic Villus Sampling (CVS)	142
5.14.2.1	Reliability of CVS Test	143
5.14.3	Cordocentesis or Percutaneous Umbilical Blood Sampling	144
5.15	Advantages and Disadvantages of Prenatal Diagnostic Tests	144
5.16	Future of Invasive Prenatal Diagnostic Tests	145
5.16.1	Indispensability of Invasive Diagnostic Tests	146
5.17	Intact Circulating Fetal Cells for Noninvasive Prenatal Tests	146
5.17.1	Scheme for Isolating Intact Fetal Cells from Maternal Blood	148
5.18	Trophoblast Retrieval and Isolation from Cervix (TRIC)	149
6.0	Newborn Screening	150
6.1	Status of Newborn Screening in Developed and Developing Countries	151
6.2	Status of Newborn Screening in Middle East and North Africa (MENA)	151
6.3	Screening Tests Recommended for Newborns in the U.S.	152
6.4	Most Common Newborn Genetic Disorders	154
6.4.1	Phenylketonuria (PKU)	154
6.4.1.1	Screening Tests Used for Diagnosis of PKU	155

6.4.2	Congenital Hypothyroidism (CHT)	155
6.4.2.1	Inheritance of CHT	155
6.4.2.2	Signs and Symptoms of CHC	155
6.4.2.3	Diagnosis of CHT	155
6.4.3	Congenital Adrenal Hyperplasia	156
6.4.3.1	Inheritance of Congenital Adrenal Hyperplasia	156
6.4.3.2	Symptoms of Congenital Adrenal Hyperplasia	156
6.4.3.3	Diagnosis of Congenital Adrenal Hyperplasia	156
6.4.4	Galactosemia	156
6.4.4.1	Signs and Symptoms of Galactosemia	157
6.4.4.2	Diagnosis of Galactosemia	157
6.4.5	Sickle Cell Disease (SCD)	157
6.4.5.1	Symptoms of SCD	157
6.4.5.2	Diagnosis of SCD	157
6.4.6	Biotinidase Deficiency	158
6.4.6.1	Inheritance of Biotinidase Deficiency	158
6.4.6.2	Signs and Symptoms of Biotinidase Deficiency	158
6.4.6.3	Diagnosis of Biotinidase Deficiency	158
6.4.7	Homocystinuria	159
6.4.7.1	Signs and Symptoms of Homocystinuria	159
6.4.7.2	Diagnosis of Homocystinuria	160
6.4.8	Maple Syrup Urine Disease (MSUD)	160
6.4.8.1	Inheritance of MSUD	160
6.4.8.2	Diagnosis of MSUD	160
7.0	Preconception/Carrier Screening	161
7.1	Introduction	161
7.2	What are the Main Commercially Available Carrier Tests on the Market?	164
7.3	Preimplantation Genetic Screening and Preimplantation Genetic Diagnosis (PGS/PGD)	167
7.4	PGS/PGD Technologies	167
7.4.1	Fluorescent in situ Hybridization (FISH)	167
7.4.2	Array Comparative Genome Hybridization (aCGH)	168
7.4.3	Single Nucleotide Polymorphism (SNP) Microarray	168
7.4.4	Oligonucleotide Genome Sequencing (OGS)	168
7.4.5	Express Genome Sequencing (EGS)	168
7.4.6	Next Generation Sequencing (NGS)	168
7.5	Strengths and Weaknesses of Currently Available PGS/PGD Technologies	169
7.6	Genetic Diseases Detected During PGD	169
7.7	PGS/PGD Testing Products in the Market	174
7.8	Cost of in vitro Fertilization and Related Procedures	176
8.0	Pregnancy, Prenatal, Newborn and PGD-Related Technologies: An Overview	178
8.1	Beta Human Chorionic Gonadotropin (β -hCG) Test	178
8.1.1	Setting up the Test Strip	178
8.1.2	Procedure of the Test	179
8.1.3	Interpretation of β -hCG Test Result	179
8.2	Pregnancy Associated Plasma Protein-A (PAPP-A) Test	180
8.2.1	Principle of PAPP-A Test	180
8.3	Maternal Serum Alpha Fetoprotein (MSAFP) Test	180
8.3.1	Principle of MSAFP Test	180
8.4	Unconjugated Estriol (uE3) Test	181
8.4.1	Principle of uE3 Test	181
8.5	Inhibin A Test	181

8.5.1	Principle of Inhibin A Test	181
8.6	Fetal Karyotyping	182
8.7	Extended Banding Chromosome Studies	182
8.8	Innovation in Invasive Prenatal Diagnosis	182
8.8.1	Microarray: An Alternative for Karyotyping	183
8.8.2	Rapid Aneuploid Detection by Quantitative Fluorescent PCR (QF-PCR)	183
8.8.2.1	Principles of QF-PCR	183
8.8.3	Fluorescence in situ Hybridization (FISH)	184
8.8.3.1	The Format of Fish Test Result	186
8.8.3.2	Commonly Used FISH-Based Tests	186
8.8.3.3	Microdeletions/Microduplications Detectable by FISH	187
8.8.3.4	Types of FISH Probes and Their Functions	187
8.8.4	Microarray-Based Comparative Genomic Hybridization (array-CGH)	188
8.9	Advances in Prenatal Screening: The Power to Know Sooner	190
8.9.1	NIPTs: An Overview of Tests and Technologies	190
8.9.1.1	Harmony Test	191
8.9.1.2	InformaSeq	192
8.9.1.3	Panorama Test	193
8.9.1.4	Prena Test	194
8.9.1.5	NIFTY Test	194
8.9.1.6	IONA Test	195
8.9.1.7	Verifi Test	196
8.9.1.8	MaterniT GENOME Test	197
8.9.1.9	MaterniT21 PLUS Test	198
8.9.1.10	HeridiT UNIVERSAL Carrier Screen	199
8.9.2	Comparison of MaterniT21 PLUS, Verifi, Harmony and Panorama Tests	199
8.9.3	U.S. Patents for NIPTs by Company	200
8.9.3.1	Selected Issued Patents of NIPTs	201
8.9.3.2	Assignees of Major U.S. Patents and their Current Licensees	202
8.9.4	Global Availability of NIPTs	202
8.9.5	Cost Effectiveness of NIPTs	204
8.9.6	Clinical Implementation Strategies to be adopted for NIPTs	204
8.9.7	Integration of NIPT into Healthcare System: Patient-Directed Model	205
8.10	Tandem Mass Spectrometry (MS/MS) in Newborn Screening	207
8.11	Fetal Ultrasound in Prenatal Screening	208
8.11.1	Types of Fetal Ultrasound Exams	208
8.11.2	Best Obstetric and Gynecological Ultrasound Systems in the Market	208
8.11.3	Best Premium Fetal Ultrasound Machines	208
8.11.3.1	Philips Epiq 7	209
8.11.3.2	GE Voluson E8	209
8.11.3.3	GE Voluson E10	210
8.11.3.4	Samsung UGEO WS80A	210
8.11.4	High-End Systems	211
8.11.4.1	Philips Epiq 5	211
8.11.4.2	Philips Affinity 70	212
8.11.4.3	GE Voluson E6	212
8.11.4.4	GE Voluson S8	212
8.11.5	Midrange Systems	213
8.11.5.1	Philips Affinity 50	213
8.11.5.2	GE Voluson S6	214
8.11.5.3	Samsung AccuVix A30	214

8.11.5.4	Philips Clear Vue 650	214
8.11.6	Economy Systems	215
8.11.6.1	Philips Clear Vue 550	215
8.11.6.2	GE Logiq P5	215
8.11.6.3	Samsung H60	216
8.11.6.4	Alpinion Ecube 7	216
8.11.7	Portable Systems	216
8.11.7.1	GE Voluson 1	217
8.11.7.2	Samsung UGEO HM70A	217
8.12	Therapeutic Genome Editing: A Breakthrough Technology	217
8.12.1	Genome Editing Technologies	218
8.12.1.1	Growing Popularity of CRISPR Kits	218
8.12.2	Therapeutic Applications of Genome Editing	219
8.12.3	The First Genetically Modified Human Embryos	220
9.0	Market Analysis	221
9.1	Preconception/Carrier Screen Market Analysis	221
9.1.1	Major Players in the Preconception/Carrier Testing Market	223
9.1.2	Market Size of Multi-Panel and Expanded Screening Market	226
9.2	Prenatal Screening and Diagnostics: Market Overview	228
9.1	Global Market for Fetal Ultrasound	228
9.1.1	Market Leaders in Fetal Ultrasound	230
9.2	Global Market for Prenatal MRI Screening	232
9.3	Global Market for Maternal Serum Screening Tests	233
9.4	Global Market for Noninvasive Prenatal Tests (NIPTs) using cffDNA	235
9.4.1	Global Market for NIPTs by Product	236
9.5	Global Market for Prenatal Diagnostic Invasive Tests	237
9.6	Global Market for Newborn Screening for Genetic Diseases	238
9.6.1	Newborn Screening Market by Technology	239
9.7	Global Market for Preimplantation Screening/Diagnosis (PGS/PGD)	246
10.0	Other Genetic Testing-Related Markets	248
10.1	Emerging Trends in Molecular Diagnostics Market	248
10.2	Emerging Trends in Liquid Biopsy Market	250
10.3	Emerging Trends in Personalized Medicine Diagnostics Market	251
10.4	Emerging Trends in in vitro Diagnostics (IVD) Market	253
11.0	Market SWOT and Strategy Analysis	256
11.1	Acquisition Activities in Prenatal Screening Industry	256
11.1.1	Acquisition of BlueGenome by Illumina	256
11.1.2	Illumina's Acquisition of Verinata	256
11.1.3	Eurofin's Joint Venture with Emory Genetics Laboratory	256
11.1.4	Roche's Acquisition of Ariosa Diagnostics	256
11.1.5	Cooper Surgical's Acquisition of Reprogenetics	256
11.2	Market Drivers	257
11.3	Market Restraints	257
11.4	Future of Prenatal Screening	257
11.5	Legislation Mandating Newborn Screening by Geography	258
11.5.1	Newborn Screening Programs in Americas	258
11.5.2	Newborn Screening Programs in Asia/Pacific	258
11.5.3	Newborn Screening Programs in Europe	258
11.5.4	Newborn Screening Programs in Middle East and Northern Africa	259
11.6	Ethical Voices against Problematic Applications of NIPT and NIPD	259
11.7	Clinical Implementation of NIPTs	260

11.7.1	Implementation of NIPTs in Developed Countries	260
11.7.3	Implementation of NIPTs in Developing and Under-Developed Countries	261
11.8	Adoption Rates for Different Prenatal Tests in the U.S.	261
12.0	Company Profiles	263
12.1	23andMe Inc.	263
12.1.1	23andMe's Agreement with Pfizer	264
12.1.2	23andMe's Agreement with Genentech	264
12.1.3	FDA's Approval for 23andMe's Screening Test for Bloom Syndrome	264
12.2	Abbott Laboratories	264
12.2.1	ARCHITECT AFP Assay	265
12.3	Abbott Molecular Inc.	265
12.3.1	AneuVysion	265
12.3.2	Cystic Fibrosis Genotyping Assay	265
12.4	Abcam plc	266
12.4.1	hCG Human ELISA Kit	266
12.5	AB Sciex LLC	266
12.6	Adaltis S.r.l	267
12.6.1	CLIAgen Free Beta-hCG Kit	267
12.7	Adaptive Biotechnologies Corp.	267
12.7.1	ImmunoSEQ Platform	267
12.7.2	ClonoSEQ	268
12.7.3	Pipeline	268
12.7.3.1	Quantifying Tumor Infiltration Lymphocytes in Solid Tumors	268
12.7.3.2	Measuring Immune Reconstitution Post Transplant	268
12.7.3.3	Diagnosing Cutaneous T-Cell Lymphoma (CTCL)	268
12.7.3.4	Therapeutics	268
12.8	Affymetrix Inc.	269
12.8.1	Microarray Solutions	269
12.8.2	Affymetrix's Collaborating Partners	270
12.8.3	Affymetrix's R&D Investment	270
12.9	Agena Biosciences Inc.	271
12.9.1	MassARRAY System	271
12.9.2	Acquisition of Sequenom's Bioscience Business by Agena Biosciences	271
12.10	Agilent Technologies Inc.	272
12.10.1	SureScan Microarray Scanner	272
12.10.2	OneSeq	272
12.11	Ambry Genetics Corp.	273
12.11.1	Clinical Diagnostic Tests	273
12.12	Analogic Corp.	274
12.12.1	Flex Focus 500	274
12.12.1	SonixTouchQ+	275
12.12.3	SonixSP Q+	275
12.13	Ariosa Diagnostics Inc.	275
12.13.1	Harmony Test	275
12.13.2	Granting of Licenses to Harmony Test	276
12.14	Ansh Labs	276
12.14.1	picoPAPP-A ELISA Kit	276
12.14.2	Inhibin A ELISA Kit	276
12.15	Appistry Inc.	277
12.15.1	GenomePilot	277
11.15.2	Ayrris for NGS Analysis	277

12.15.3	Variant Annotation and Analysis Suite	277
12.15.4	CloudDx Translational	277
12.15.5	CloudDx Clinical	277
12.15.6	Appistry's Partnership with LifeMap Sciences	278
12.16	ARUP Laboratories	278
12.16.1	Prenatal Screening and Diagnosis	278
12.16.2	Next-Generation Sequencing (NGS)	278
12.16.3	Noninvasive Prenatal Test for Aneuploids	279
12.17	AssureRx Health Inc.	279
12.17.1	GeneSight Psychotropic	279
12.17.2	GeneSight Analgesic	279
12.17.3	GeneSight ADHD	279
12.17.4	GeneSight MTHFR	280
12.18	Asuragen Inc.	280
12.18.1	AmplideX FMR1 PCR	280
12.18.2	AmplideX FMR1 mPCR	280
12.18.3	AmplideX Controls	280
12.18.4	Quantidex Pan Cancer Kit	281
12.18.5	Quantidex BCR/ABL1 Quant Kit	281
12.18.6	Quantidex DNA Assay	281
12.18.7	Signature Technology	281
12.18.8	Signature KRAS Mutations	281
12.18.9	Signature BRAF Mutations	281
12.18.10	Signature LTx v2.0	282
12.18.11	Signature NPM1 Mutations	282
12.19	Athena Diagnostics Inc.	282
12.20	AutoGenomics Inc.	282
12.20.1	INFINITI System	283
12.21	Base4 Innovation Ltd.	283
12.21.1	Microdroplet Sequencing	283
12.22	Beckman Coulter Inc.	283
12.22.1	SPRIworks System I for Illumina Genome Analyzer	284
12.22.2	SPRIworks HT for Illumina NGS Platform	284
12.22.3	SPRIselect Reagent Kit	284
12.22.4	Automated Sample Preparation	284
12.22.5	Genomic Services	284
12.22.6	Access Total Beta-hCG Reagent	285
12.22.7	Access Inhibin A Assay	285
12.23	erry Genomics Co., Ltd.	285
12.23.1	Bambni Test	285
12.23.2	Berry's Partnership with Illumina	285
12.24	Bina Technologies Inc.	286
12.24.1	Bina RAVE	286
12.24.2	Bina AAiM	286
12.24.3	Bina's Collaboration with AsraZeneca	286
12.25	Bio-Rad (Israel) Laboratories Inc.	287
12.26	BGI	287
12.27	Blueprint Genetics Oy	288
12.27.1	Services	288
12.28	Boreal Genomics Inc.	288
12.28.1	OnTarget Mutation Detection System	289

12.28.2	Aurora Platform	289
12.29	Cambridge Epigenetix Ltd.	289
12.29.1	TrueMethyl Seq Kit	289
12.29.2	TrueMethyl Array	290
12.30	Caris Lifesciences	290
12.30.1	ADAPT Biotargeting System	290
12.30.2	Caris Molecular Intelligence	290
12.30.3	Collaboration between Caris Lifesciences and Syapse	290
12.31	CeGaT GmbH	291
12.31.1	NGS Service	291
12.31.2	ADME Research Panel	291
12.31.3	Forschungsexom	292
12.32	Centogene AG	292
12.33	Chromsystems Instruments & Chemicals GmbH	292
12.34	Chronix Biomedical Inc.	293
12.34.1	Technology	293
12.35	Claritas Genomics Inc.	293
12.36	CLC bio A/S	296
12.36.1	Products	296
12.37	Combimatrix Corp.	297
12.37.1	CombiSNP Array for Prenatal Diagnosis	297
12.37.2	CombiPGS	297
12.38	Contec Medical Systems Co., Ltd.	303
12.38.1	CMS600P B-Ultrasound Diagnostic System	303
12.38.2	CMS600B3 B-Ultrasound Diagnostic System	303
12.39	Coriell Life Sciences Inc.	303
12.39.1	GeneDose	303
12.40	Correlagen Diagnostics Inc.	304
12.41	Counsyl Inc.	306
12.41.1	Family Prep Screen	306
12.41.2	Informed Pregnancy Screen	306
12.41.3	Inherited Cancer Screen	307
12.42	Courtagen Life Sciences Inc.	307
12.43	Creative Diagnostics	307
12.43.1	Alpha-Fetoprotein, AFP ELISA Kit	308
12.43.2	hCG ELISA Kit	308
12.43.3	Human Free Estriol ELISA Kit	308
12.44	Cynvenio Biosystems Inc.	308
12.44.1	LiquidBiopsy	309
12.44.2	ClearID	309
12.44.3	Thermo Fisher's Distribution Agreement with Crynvenio	309
12.44.4	Cynvenio's Collaboration with the University of Southern Denmark	309
12.45	Diagnostic Automation/Cortez Diagnostics Inc.	309
12.46	Demeditec Diagnostics GmbH	310
12.46.1	Estriol, Free/Uncojugated ELISA	310
12.47	DRG International Inc.	310
12.47.1	DRG PAPP-A ELISA	311
12.48	DNA Electronics Ltd.	311
12.48.1	Genalysis	311
12.49	DNA Link Inc.	311
12.49.1	Services	312

12.49.2	Partnership between Affymetrix and DNA Link Inc.	312
12.49.3	DNAGPS	312
12.49.4	AccuID	313
12.50	DNAnexus Inc.	313
12.50.1	Adoption of DNAnexus' Cloud Genomics Platform by Natera	313
12.51	Eagle Biosciences Inc.	314
12.51.1	Alport Syndrome Kit	314
12.51.2	Free Beta-hCG ELISA	314
12.52	Eagle Genomics Ltd.	314
12.52.1	EagleCore	315
12.52.2	EagleNsembl	315
12.53	Enzymatics Inc.	315
12.53.1	Reagents	315
12.53.2	SPARK DNA Sample Preparation Kit	315
12.54	Esoate SpA	316
12.54.1	MyLabGamma	316
12.54.2	MyLab GOLD Platform	316
12.54.3	MyLab 50	316
12.54.4	MyLab 40	316
12.54.5	MyLab 25Gold	317
12.55	Eurofins MWG Operon Inc.	317
12.55.1	Products and Services	317
12.56	Exiqon A/S	318
12.56.1	Products and Services	318
12.57	Fakuda Denshi Co., Ltd.	319
12.57.1	UF-400AX	319
12.57.2	UF-550XTD	319
12.57.3	UF-760AG	320
12.57.4	UF-870AG	320
12.58	GATC Biotech AG	321
12.58.1	Sanger Sequencing	321
12.59	GE Healthcare Ltd.	321
12.59.1	VScan	322
12.59.2	VScan with Dual Probe	322
12.59.3	Logiq P5	322
12.59.4	Logiq P6	322
12.59.5	GE Venue 50	322
12.59.6	GE Venue 40	323
12.59.7	Logiq S8	323
12.59.8	Logiq E9	323
12.60	GenapSys Inc.	323
12.60.1	GENIUS	323
12.61	Gene by Gene Ltd.	323
12.62	Genection Inc.	324
12.63	GeneDx Inc.	325
12.63.1	Cytogenetics and Biochemical Tests	325
12.63.2	Deletion/Duplication Analysis	326
12.63.3	Carrier Mutation-Specific Testing	326
12.64	GenePeeks Inc.	326
12.64.1	Matchright Technology	327
12.65	Genesis Genetics	327

12.65.1	GeniSeq24	327
12.65.2	UltraPGD	327
12.65.3	ArrayCGH	327
12.66	Genetadi Biotech S.L.	328
12.66.1	AMNIOCHIP	328
12.66.2	FERTICHIP	328
12.66.3	PRENATAL GENE	328
12.67	Genoma Group Srl	329
12.68	Genomed AG	329
12.68.1	Aneufast	329
12.69	GenPath Diagnostics	330
12.69.1	InheriGen, InheriGen Plus and InheriGen Tx	330
12.69.2	Prenatal Tests	330
12.70	Genway Biotech Inc.	330
12.71	Good Start Genetics Inc.	331
12.71.1	EmbryVu	331
12.72	Hitachi Medical Systems America Inc.	331
12.72.1	Arietta 70	331
12.72.2	ProSound Alpha 7	331
12.72.3	Noblus	332
12.72.4	ProSound F37	332
12.73	Hologic Inc.	332
12.73.1	InPlex CF Molecular Test	332
12.73.2	Rapid fFN Test	332
12.74	Illumina Inc.	333
12.74.1	The Verifi Prenatal Test	333
12.75	INEX Innovations Exchange Pte Ltd.	334
12.75.1	iGene	335
12.75.2	FlashFISH	335
12.75.3	INEX's Collaborative Agreement with BGI	335
12.76	Invitae Corp.	335
12.77	Laboratory Corporation of America Inc.	336
12.77.1	Services	336
12.78	LifeCodexx AG	337
12.78.1	Prena Test	337
12.79	Monobind Inc.	337
12.79.1	Fertility VAST Panel: HCG, FSH, LH, SPRL	337
12.79.2	PAPP-A Test	338
12.80	Multiplicom NV	338
12.80.1	Clarigo	338
12.81	Myriad Genetics	338
12.82	Natera Inc.	339
12.82.1	Panorama Prenatal Screen	339
12.82.1.1	Accuracy of Panorama Test	339
12.82.1.2	Minimal False Negatives in Panorama	340
12.82.2	Horizon Carrier Screening	340
12.82.3	Spectrum Preimplantation Test	341
12.82.4	Natera's 24-chromosome PGS	342
12.82.5	Anora Miscarriage Test	342
12.82.6	Prenatal Paternity Test	342
12.82.7	Agreement between Natera and LifeLabs	342

12.83	Natus Medical Inc.	343
12.83.1	ABaer	343
12.83.2	Algo 5	343
12.83.3	Algo 3i	343
12.83.4	AuDX	344
12.83.5	Echo-Screen III	344
12.84	NewGene Ltd.	344
12.84.1	Hereditary Disorders	345
12.84.2	Alport Syndrome	345
12.84.3	Aortopathy Panel	345
12.84.4	RASopathy Gene Panel	345
12.84.5	Familial Hypercholesterolaemia	346
12.85	NIPD Genetics Ltd.	346
12.85.1	VERACITY Test (NIPT)	346
12.86	Oxford Gene Technology (OGT)	347
12.86.1	SureSeq NGS Library Preparation Kit	347
12.86.2	CytoSure Embryo Screen Array	347
12.86.3	Cytocell FISH Probes	347
12.86.4	CytoSure Embryo Screen Array	347
12.86.5	CytoSure Aneuploidy Array	347
12.86.6	CytoSure Chromosome X Arrays	348
12.87	Parabase Genomics Inc.	348
12.87.1	NewbornDx Test	348
12.88	Pathway Genomics Corp.	349
12.88.1	Carrier Screening	349
12.89	PerkinElmer Life and Analytical Sciences Inc.	349
12.89.1	DELFIAXpress PIGF Assay	349
12.89.2	DELFIAXpress PAPP-A Kit	349
12.89.3	AutoDELFIAXpress PAPP-A Kit	350
12.89.4	StepOne Newborn Screens	350
12.90	Premaitha Health PLC	350
12.90.1	IONA Test	350
12.90.2	Premaitha's Investment Agreement with Thermo Fisher	351
12.91	Progenity Inc.	351
12.91.1	nxtPanel Test	351
12.91.2	Verifi Test	351
12.91.3	Acquisition of Carmenta Bioscience by Progenity	352
12.92	Qiagen N.V.	352
12.92.1	Next-Generation Sequencing (NGS)	352
12.92.2	Target Enrichment Solutions	353
12.92.3	Library Construction	353
12.93	Quest Diagnostics Inc.	353
12.93.1	QNatal Advanced	354
12.93.2	Inhibin A	354
12.94	Ravgen Inc.	354
12.94.1	Prenatal Down Syndrome Testing	354
12.94.2	Single Gene Disorder Testing	354
12.95	Recombine Inc.	355
12.95.1	CarrierMap	355
12.96	Reproductive Genetics Institute Inc.	355
12.97	Reprogenetics Laboratories	355

12.97.1	Array CGH (aCGH)	356
12.97.2	Single Gene Disorder Testing	356
12.97.3	WaferGen Biosystems' Supply Agreement with Reprogenetics	356
12.98	Sebia Inc.	356
12.99	Sequenom Inc.	357
12.99.1	MaterniT GENOME Test	357
12.99.1.1	Sensitivity and Specificity of MaterniT GENOME Test	357
12.99.2	MaterniT21 PLUS	357
12.99.2.1	Sensitivity and Specificity of MaterniT21 PLUS	358
12.99.3	HerediT UNIVERSAL Carrier Screen	359
12.99.4	VisibiliT Prenatal Test	359
12.99.5	HerediT Cystic Fibrosis Carrier Screen	360
12.99.5.1	Clinical Data for HerediT	360
12.99.6	SensiGene Fetal RHD Genotyping	360
12.99.7	NextView Prenatal Diagnostic Tests	361
12.100	SeraCare Life Sciences Inc.	362
12.100.1	Seraseq Trisomy 21 Aneuploidy Reference Material	362
12.101	Siemens Healthcare	362
12.101.1	Acuson S2000	362
12.101.2	Acuson X700	363
12.101.3	Acuson X600	363
12.101.4	Acuson X300 PE	363
12.101.5	Acuson X150	363
12.101.6	Acuson Antares	363
12.101.7	Acuson P300	363
12.102	Sophia Genetics SA	334
12.102.1	Clinical Genomic Modules	364
12.103	SpOtOn Clinical Diagnostics Ltd.	364
12.103.1	Newborn Screening	364
12.103.2	Ante-Natal Testing	365
12.104	Stra Biotech GmbH	365
12.105	Sygnis AG	365
12.105.1	TruePrime Single Cell WGA Kit	366
12.105.2	TruePrime WGA Kit	366
12.105.3	TruePrime RCA Kit	366
12.105.4	SunScript Reverse Transcriptase RNaseH+ and RNaseH- Kits	366
12.105.5	SensiPhi/QualiPhi	366
12.106	SynapDx Corporation	366
12.106.1	ASD Diagnosis	367
12.107.1	Thermo Fisher's Brands	367
12.108	Transgenomic Inc.	368
12.108.1	Technology Suite	368
12.108.2	MX-ICP Technology	368
12.108.3	ICEme Kit	368
12.108.4	Other Products	369
12.109	Trivitron Healthcare Private Ltd.	369
12.110	Trovagene Inc.	370
12.110.1	PCM BRAF V600E Mutation Detection Test	370
12.110.2	PCM KRAS Mutation Detection Test	370
12.110.3	PCR EGFR Mutation Detection Test	370
12.110.4	HPV HR Detection Test3	370

12.111	Tute Genomics Inc.	371
12.111.1	Tute Platform	371
12.112	Warp Drive Bio LLC	372
12.112.1	Wrap’s New Approach	372
12.112.2	Chemomemes	372
12.112.3	Genomic Search Engine	372
12.113	ZS Genetics Inc.	372
12.113.1	3G Sequencing	373
12.114	Zymo Research Corporation	373
12.114.1	DNA Methylation Products	373
12.114.1.1	Bisulfite Conversion	373
12.114.1.2	Methylated DNA Standards	373
12.114.1.3	DNA Methyltransferases	374
12.114.1.4	5-mC ELISA	374
12.114.1.5	5-mC Antibodies and Immunoprecipitation	374
12.114.1.6	Region-Specific DNA Methylation Analysis	374
12.114.1.7	Global 5-mC Quantification	374
12.114.1.8	Genome-wide 5-mC Analysis	375
12.114.2	DNA Purification Products	375
12.114.2.1	DNA Clean-up	375
12.114.2.2	Plasmid DNA Purification	375
12.114.2.3	Genomic DNA	375
12.114.2.4	Microbial and Environmental DNA Isolation	375
12.114.2.5	DNA/RNA Co-Purification	376
12.114.2.6	Sample Collection and Stabilization	376
12.114.2.7	DNA Ladders	376
12.114.2.8	Enzymes	376
12.114.2.9	High-Throughput/Automated Isolation	376
12.114.2.10	DNA Analysis Kits	377
12.114.3	Other Products	377

APPENDIX

Appendix 1: Representative Companies in Prenatal and Maternal Diagnostics and their Products	378
Appendix 2: Sources for Tables and Graphs	381

INDEX OF FIGURES

Figure 1.1: Summary of Prenatal Screening, Prenatal Diagnosis, Newborn Screening and PGS/PGD Markets, Through 2021	27
Figure 2.1: Risk of Down Syndrome and Chromosomal Abnormalities Due to AMA	32
Figure 2.2: Maternal Age and Pregnancy Loss Rate	33
Figure 2.3: Risk of Cesarean Section with Increasing AMA	34
Figure 2.4: Risk of Gestational Diabetes with AMA	35
Figure 2.5: Risk of Placenta Previa with AMA	36
Figure 2.6: Delayed First Pregnancy in the U.S.	37
Figure 2.7: First Birth Rates for 35-39 Aged U.S. Women by Race	38
Figure 2.8: Pre-Existing Chronic Diseases among Women of Reproductive Ages in the U.S.	46
Figure 2.9: Chronic Disease Risk Behaviors and Risk Factors among Women of Reproductive Ages in the U.S.	46
Figure 2.10: Prevalence of Preeclampsia during Pregnancy by Race/Ethnicity in the U.S.	48

Figure 2.11: Prevalence of Preeclampsia by Maternal Age in the U.S.	50
Figure 2.12: Prevalence of Gestational Diabetes by Maternal Age in the U.S.	50
Figure 2.13: Prevalence of Gestational Diabetes by Maternal Race/Ethnicity in the U.S.	50
Figure 2.14: Causes of Preterm Labor	51
Figure 2.15: Prevalence of Preterm Births in the U.S. by Stage	53
Figure 2.16: Prevalence of Preterm Births in the U.S. by Race/Ethnicity	54
Figure 2.17: Prevalence of Preterm Births in the U.S. by Plurality of Birth	55
Figure 2.18: Prevalence of Preterm Births in the U.S. by Maternal Age	56
Figure 2.19: Prevalence of Multiple Births in the U.S.	57
Figure 3.1: Inheritance of Autosomal Dominant Faulty Gene When One Parent is a Carrier	66
Figure 3.2: Inheritance of Autosomal Dominant Faulty Gene When Both Parents are Carriers	66
Figure 3.3: Percent of Patients taking Sweat Chloride Test Reported in the U.S. Registry	68
Figure 3.4: Age at CF Diagnosis for all People Reported in the U.S. Registry, 2013	68
Figure 3.5: Distribution of Race/Ethnicity among People with CS in the U.S., 2013	69
Figure 3.6: Percent of New CF Diagnosis in U.S. Newborn Screenings, 1990-2013	70
Figure 3.7: The Six Most Common CFTR Mutations in the U.S.	71
Figure 3.8: Autosomal Recessive Inheritance when Both Parents are Carriers	78
Figure 3.9: Autosomal Recessive Inheritance with Carrier Mother and Non-Carrier Father	78
Figure 3.10: Autosomal Recessive Inheritance from Homozygous Recessive Mother and Carrier Father	78
Figure 3.11: Autosomal Recessive Inheritance from Two Affected Parents	79
Figure 3.12: Inheritance Pattern of Sex-Linked Dominant Disorder with Affected Mother and Carrier Father	85
Figure 3.13: X-Linked Recessive Inheritance with a Carrier Mother and Non-Carrier Father	91
Figure 3.14: X-Linked Recessive Inheritance with Normal Mother and Affected Father	91
Figure 3.15: Incidence of Down Syndrome by Maternal Age in the U.S.	98
Figure 3.16: Prevalence of Trisomies in the U.S.	103
Figure 3.17: Relative Frequencies of Chromosomal Anomalies in Spontaneous Abortions	104
Figure 3.18: Maternal Age and Chromosomal Aneuploidy Detected at Amniocentesis	106
Figure 5.1: Genetic Disorders (%) Detectable by Prenatal Testing Methods	139
Figure 5.2: Nuchal Translucency as Seen in an Ultrasound Scan	140
Figure 5.3: The Amniocentesis Procedure	142
Figure 5.4: Chorionic Villus Sampling Procedure	143
Figure 5.5: Transvaginal CVS Procedure	143
Figure 5.6: Decline in Number of Amniocentesis at Yale New Haven Hospital and Bridgeport Hospital in the U.S. between 2011 and 2013	146
Figure 5.6: Scheme for Isolating Intact Fetal Cells for Prenatal Genetic Diagnosis	146
Figure 6.1: Number of Newborn Genetic Diseases Screened in Selected Countries	151
Figure 6.2: The Top Four Countries with Homocystinuria Population (per 100,000)	159
Figure 7.1: Indications for PGD	167
Figure 8.1: Markings on the Test Strip	178
Figure 8.2: Procedure of β -hCG Test	179
Figure 8.3: Interpretation of β -hCG Test Result	179
Figure 8.4: Fetal Karyotype Showing Trisomy 21 (Down Syndrome)	182
Figure 8.5: Peak Heights Indicating Aneuploidy in QF-PCR Study	184
Figure 8.6: Diagrammatic Representation of Steps Involved in FISH Test	185
Figure 8.7: FISH Test Showing Chromosomal Deletion	185
Figure 8.8: Steps Involved in Array-CGH	189
Figure 8.9: History of Innovations in NIPTs from 2011-2015	190
Figure 8.10: Detection Rate of Harmony Test Compared with Traditional Maternal Serum Tests	191
Figure 8.11: Global Availability of NIPTs	203

Figure 8.12: Preference of NIPTs by Pregnant Women at Santa Clara Valley Medical Center	206
Figure 8.13: Patient-Directed Model of Integrating NIPTs into Healthcare Setting	206
Figure 8.14: Growing Popularity of CRISPR-Cas9 Kits	219
Figure 9.1: Global Carrier Screen Test Market 2015-2020	221
Figure 9.2: Geographical Breakdown of Carrier Screen Test Market, USA, EU, RoW 2015-2020	222
Figure 9.3: Ultrasound Imaging Market Share (%) by Clinical Application	229
Figure 9.4: Global Market for Fetal Ultrasound Screening by Geography (U.S., Europe, RoW), Through 2021	230
Figure 9.5: Global Fetal Ultrasound Market Share by Company, 2014	232
Figure 9.6: Global Market for MRI Prenatal Screening by Geography (U.S., Europe, RoW), Through 2021	233
Figure 9.7: Global Market for Maternal Serum Screening Tests by Geography (U.S., Europe, RoW), Through 2021	234
Figure 9.8: Share of NIPTs Market by Geography (North America, Europe, RoW)	235
Figure 9.9: Global Market for NIPTs by Geography (North America, Europe, RoW), Through 2021	236
Figure 9.10: Global Market for NIPTs by Product	237
Figure 9.11: Global Market for Prenatal Invasive Diagnostic Tests by Geography (U.S., Europe, RoW), Through 2021	238
Figure 9.12: Global Market for Newborn Screening, Through 2021	239
Figure 9.13: Global Market for Newborn Screening by Technology, Through 2021	240
Figure 9.14: Global Market for MS/MS in Newborn Screening, Through 2021	241
Figure 9.15: Global Market for Pulse Oximetry in Newborn Screening, Through 2021	242
Figure 9.16: Global Market for Enzyme-Based Assays in Newborn Screening, Through 2021	243
Figure 9.17: Global Market for DNA Assays in Newborn Screening, Through 2021	244
Figure 9.18: Global Market for Electrophoresis in Newborn Screening, Through 2021	245
Figure 9.19: Geographical Share of PGS/PGD Market	246
Figure 9.20: Global Market for PGS/PGD by Geography (North America, Europe, RoW)	247
Figure 10.1: Global Market for Molecular Diagnostics, Through 2021	249
Figure 10.2: Global Market for Liquid Biopsy by Geography (North America, Europe, RoW), Through 2021	251
Table 10.3: Global Market for Personalized Medicine by Business Segment, Through 2021	253
Figure 10.4: Percent Share of IVD Market by Business Segments	254
Figure 10.5: Global IVD Market by Geography (North America, Europe, RoW), Through 2021	255
Figure 12.1: Comparison of False Negative Rates	340
Figure 12.2: Sensitivity and Specificity of MaterniT GENOME Test	358

INDEX OF TABLES

Table 1.1: Summary of Prenatal Screening, Prenatal Diagnosis, Newborn Screening and PGS/PGD Markets, Through 2021	26
Table 2.1: Risk of Down Syndrome and Chromosomal Abnormalities Due to AMA	32
Table 2.2: Maternal Age and Pregnancy Loss Rate	33
Table 2.3: Risk of Cesarean Section with Increasing AMA	34
Table 2.4: Risk of Gestational Diabetes with AMA	35
Table 2.5: Risk of Placenta Previa with AMA	36
Table 2.6: Delayed First Pregnancy in the U.S.	37
Table 2.7: First Birth Rates for 35-39 Aged U.S. Women by Race	38
Table 2.8: Maternal and Fetal Concerns due to Pre-Existing Maternal Medical Issues	40
Table 2.9: Pregnancy Outcome in Women with Renal Diseases	40
Table 2.10: Pregnancy Outcome in Women with Pre-Existing Thyroid Disease	41
Table 2.11: Risks Associated with Obesity in Pregnant Women	42

Table 2.12: Pregnancy Complications in Asthmatic Women	42
Table 2.13: Pregnancy Complications and Neonatal Outcome in Women with Epilepsy	43
Table 2.14: Maternal and Fetal Complications in Women with Autoimmune Diseases	44
Table 2.15: Complications due to Hemoglobinopathies in Pregnancy	45
Table 2.16: Prevalence of Gestational Diabetes in the U.S.	49
Table 2.17: Countries with Higher and Lower Rates of Preterm Births	52
Table 2.18: Prevalence of Preterm Births in the U.S. by Stage	53
Table 2.19: Prevalence of Preterm Births in the U.S. by Race/Ethnicity	54
Table 2.20: Prevalence of Preterm Births in the U.S. by Plurality of Birth	55
Table 2.21: Prevalence of Preterm Births in the U.S. by Maternal Age	56
Table 2.22: Related Complications of Placenta Previa	57
Table 2.23: Mode of Delivery for Breech Presentation	58
Table 2.24: Perinatal Outcome due to Meconium Stained Liquor	58
Table 2.25: Pregnancy Outcome due to Polyhydramnios	59
Table 2.26: Causes of Fetal Growth Restriction	59
Table 2.27: Prevalence of Congenital Cardiovascular Diseases in the U.S.	61
Table 3.1: Worldwide Prevalence of Huntington Disease by Selected Country	63
Table 3.2: Prevalence of 25 Most Common CFTR Mutations in the U.S., 2013	70
Table 3.3: Molecular Diagnostic Tests for Canavan Disease	72
Table 3.4: Incidence of Sickle Cell Disease in the U.S.	76
Table 3.5: Red Blood Cell Indices in Beta-Thalassaemia	76
Table 3.6: Molecular Genetic Tests for Beta-Thalassaemia	77
Table 3.7: Chances of Inheriting a Single Gene Disorder	80
Table 3.8: More Common Recessive Disease Traits in Selected Ethnic Groups	80
Table 3.9: A Comprehensive List of Genetic Disorders	81
Table 3.10: Turnaround Time and Average Cost for Hemophilia Genetic Tests	87
Table 3.11: Incidence of Chromosomal Abnormalities	93
Table 3.12: Karyotypes Commonly Associated with Klinefelter Syndrome	94
Table 3.13: Features of Turner Syndrome in Different Age Groups	95
Table 3.14: Some Complications of Trisomy 21 (Down Syndrome)	96
Table 3.15: Incidence of Down Syndrome by Maternal Age	98
Table 3.16: Developmental Delay in Children with Down Syndrome	99
Table 3.17: Frequently Observed Anomalies in Babies with Trisomy 18	100
Table 3.18: Common Clinical Features of Trisomy 13	101
Table 3.19: Congenital Anomalies Associated with Triploidy	102
Table 3.20: Relative Frequencies of Different Chromosomal Anomalies in Spontaneous Abortions	104
Table 3.21: Maternal Age-Related Frequencies of Aneuploid Fetuses Detected Prenatally	104
Table 3.22: Clinical Features of Common Chromosomal Aneuploidy	105
Table 3.23: Maternal Age and Chromosomal Aneuploidy	105
Table 3.24: Sensitivity and Specificity of Maternal Serum and Ultrasound Tests for Aneuploids	106
Table 3.25: Common Autosomal Deletions, Resulting Syndromes and Clinical Features	107
Table 3.26: Common Autosomal Microdeletion Syndromes	110
Table 3.27: Commonly Encountered Problems in Prader-Willi Syndrome	112
Table 3.28: Tests for Prader-Willi Syndrome	113
Table 3.29: Molecular Genetic Tests for CATCH 22 Syndrome	116
Table 3.30: Autosomal Duplication Syndromes	118
Table 3.31: Molecular Genetic Tests for Beckwith-Wiedemann Syndrome	119
Table 3.32: Molecular Diagnostic Tests for CMT1A	120
Table 4.1: Genetic Counseling Services by DTC GT Companies	124
Table 4.2: A List of Genetic Counseling Companies and Their Websites	125
Table 5.1: Major Prenatal Screening Tests during the First and Second Trimesters	126

Table 5.2: Other Routine and Non-Routine Prenatal Screening Tests	126
Table 5.3: hCG Levels from Date of Conception to 40th Week	127
Table 5.4: Selected β -hCG Kits and Manufacturers	128
Table 5.5: Selected PAPP-A Kits and Manufacturers	128
Table 5.6: Selected MSAFP Test Kits and Manufacturers	129
Table 5.7: Selected uE3 Test Kits and Manufacturers	129
Table 5.8: Selected Inhibin-A Test Kits and Manufacturers	130
Table 5.9: Selected Hexosaminidase Test Kits and Manufacturers	130
Table 5.10: Comparison of the Four Maternal Serum Screening Analyte Patterns	131
Table 5.11: The Five Popular Commercially Available Noninvasive Prenatal Tests (NIPTs)	131
Table 5.12: Sensitivity and Specificity of NIPTs	132
Table 5.13: Diagnostic Applications of cffDNA	132
Table 5.14: Time of Availability of cffDNA in Maternal Blood	133
Table 5.15: The Costs of NIPTs by Region/Country	133
Table 5.16: Costs of NIPTs by Product in the U.S.	134
Table 5.17: History of Aneuploidy Screening	134
Table 5.18: NIPT Methods for Detecting Aneuploidy	135
Table 5.19: Comparison of Amniocentesis and NIPTs	136
Table 5.20: Advantages and Disadvantages of NIPTs	137
Table 5.21: Comparison of Performance Criteria for Commonly Used Prenatal Tests	137
Table 5.22: Comparison of NIPT Detection Rates with Traditional Tests	138
Table 5.23: False Positive Rates of NIPTs Compared with those of Traditional Tests	138
Table 5.24: Different Applications of Ultrasound in Different Trimesters	140
Table 5.25: MRI Indications for Prenatal Screening when Ultrasound Screening is Inadequate	141
Table 5.26: Prenatal Diagnostic Tests by Pregnancy Stage	141
Table 5.27: Comparison of CVS and Amniocentesis	144
Table 5.28: Advantages and Disadvantages of Prenatal Diagnostic Tests	145
Table 5.29: Comparison of Prenatal Tests using Cell-Free Fetal DNA (cffDNA) and Intact Fetal Cells from Maternal Blood	148
Table 6.1: Thirty One Core Conditions Detected During Newborn Screening	150
Table 6.2: Categories of Newborn Genetic Disorders	
152	
Table 6.3: Metabolic Genetic Disorders Detectable by MS/MS and their Scores	153
Table 6.4: Incidence of PKU by Region	154
Table 6.5: Molecular Genetic Tests for Biotinidase Deficiency	158
Table 7.1: Number of Genetic Disease States with Carrier Status	161
Table 7.2: Carrier Risk of Most Common Genetic Diseases by Ethnic Group	162
Table 7.3: Select Commercially Available Genetic Assays for Carrier Screening by Company and Diseases Detected	165
Table 7.4: Advantages and Disadvantages of Currently Available PGS/PGD Technologies	169
Table 7.5: Genetic Diseases Detected During PGS/PGD	169
Table 7.6: Currently Available Products for PGS/PGD	175
Table 7.7: Cost of in vitro Fertilization and Related Procedures	176
Table 8.1: Karyotype vs. Microarray	183
Table 8.2: The Format of FISH Test Result	186
Table 8.3: Some Commonly Used FISH-Based Tests	186
Table 8.4: Microdeletions/Microduplications Detectable by FISH	187
Table 8.5: FISH Probes and Functions	188
Table 8.6: Presentation Format of Array-CGH Test Report	189
Table 8.7: Harmony vs. Traditional Down Syndrome Tests	191
Table 8.8: Predictive Value, Sensitivity and Specificity of InformaSeq Test	192

Table 8.9: Detection Rates of Panorama Test	193
Table 8.10: NIFTY Test Options	194
Table 8.11: Clinical Data for IONA Test	196
Table 8.12: Sensitivity and Specificity of Verifi Test	197
Table 8.13: Sensitivity and Specificity of Verifi's Microdeletion Panel	197
Table 8.14: Comparison of MaterniT GENOME Test and Karyotype	198
Table 8.15: Sensitivity and Specificity of MaterniT GENOME Test	198
Table 8.16: MaterniT21 PLUS' Independent Validation	199
Table 8.17: The Three Panels Offered by HeridiT UNIVERSAL Carrier Screen	199
Table 8.18: Comparison of the Four Major NIPT Products available in the U.S. Market	200
Table 8.19: U.S. Patents for NIPTs by Company	200
Table 8.20: Selected Issued Patents of NIPTs	201
Table 8.21: Major U.S. Patents and Applications	202
Table 8.22: Countries in Which NIPT is currently Marketed	203
Table 8.23: Detection, Uptake, False Positive and Failure Rates for NIPTs	204
Table 8.24: Cost of Different Prenatal Screens	204
Table 8.25: Disease Types Targeted by Different Nuclease Platforms	220
Table 9.1: Global Carrier Screen Test Market 2015-2020 US\$ Million	222
Table 9.2: Geographical Carrier Screen Test Market 2015-2020 US\$ Millions, USA, EU, RoW	222
Table 9.3: Global Market for Fetal Ultrasound Screening by Geography (U.S., Europe, RoW), Through 2021	229
Table 9.4: Global Fetal Ultrasound Market Share by Company, 2014	231
Table 9.5: Global Market for MRI Prenatal Screening by Geography (U.S., Europe and RoW), Through 2021	233
Table 9.6: Global Market for Maternal Serum Screening Tests by Geography (U.S., Europe, RoW), Through 2021	234
Table 9.7: Global Market for NIPTs by Geography (North America, Europe, RoW), Through 2021	235
Table 9.8: Global Market for NIPTs by Product	236
Table 9.9: Global Market for Prenatal Invasive Diagnostic Tests by Geography (U.S., Europe, RoW), Through 2021	237
Table 9.10: Global Market for Newborn Screening by Technology, Through 2021	240
Table 9.11: Global Market for PGS/PGD by Geography (North America, Europe, RoW), Through 2021	246
Table 10.1: Global Market for Liquid Biopsy by Region (North America, Europe, RoW), Through 2021	251
Table 10.2: Global Market for Personalized Medicine by Business Segment, Throgh 2021	252
Table 10.3: Global IVD Market by Geography (North America, Europe, RoW), Through 2021	254
Table 11.1 Adoption Rates for Different Prenatal Tests in the U.S.	261
Table 12.1: Financial Data for Affymetrix	270
Table 12.2: Selected Financial Data for Agilent Technologies	272
Table 12.3: Comparison of Harmony and Other Traditional Tests	276
Table 12.4: CombiSNP Prenatal Targeted Array Disorder List	298
Table 12.5: Genetic Tests Offered by Correlagen by Gene and Disease	304
Table 12.6: GeneDx's Cytogenetics and Biochemical Tests	325
Table 12.7: Hologic's Financial Data	333
Table 12.8: Performance of Verifi Test	333
Table 12.9: Verifi Prenatal Test Lab Partners in the U.S.	334
Table 12.10: Illumina's Financial Data	334
Table 12.11: Comparison of Prenatal Test Performance	339
Table 12.12: Comparison of False Negative Rates	340
Table 12.13: A Small Sample of Diseases Screened by Horizon Test	341

Table 12.14: Natus Medical’s Financial Data	344
Table 12.15: Clinical Data for IONA Test	351
Table 12.16: Sensitivity and Specificity of MaterniT GENOME Test	357
Table 12.17: Sequenom’s Financial Data	358
Table 12.18: Sensitivity and Specificity of MaterniT21 PLUS Test	359
Table 12.19: Three Options Offered by HeridiT UNIVERSAL Carrier Screen	359
Table 12.20: Clinical Evaluation Performance of VisibiliT Prenatal Test	360
Table 12.21: CF Detection Rates for Standard and Expanded Panels	360
Table 12.22: Accuracy, Sensitivity and Specificity of SensiGene Fetal RHD	361
Table 12.23: NextView Diagnostic Test Platforms	361
Table 12.24: Trovogene’s Financial Data	371
Table Ap. 1.1: Participating Companies and their Products and Services	378

